| NCT ID | NCT03192774 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Segeberger Kliniken GmbH |
| Condition | Aortic Valve Stenosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2007-09 |
| Primary Completion | 2022-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2007-09 with a primary completion date of 2022-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A single center registry including all patients treated with TAVI at the Heart Center, Bad Segeberg, Germany
Eligibility Criteria
Inclusion Criteria: * All patients treated with TAVI Exclusion Criteria: * None
Contact & Investigator
Mohamed Abdel-Wahab, MD
✉ msabdelwahab@gmail.comGert Richardt, MD
STUDY CHAIR
Heart Center, Segeberger Kliniken
Frequently Asked Questions
Who can join the NCT03192774 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Aortic Valve Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03192774 currently recruiting?
Yes, NCT03192774 is actively recruiting participants. Contact the research team at msabdelwahab@gmail.com for enrollment information.
Where is the NCT03192774 trial being conducted?
This trial is being conducted at Bad Segeberg, Germany.
Who is sponsoring the NCT03192774 clinical trial?
NCT03192774 is sponsored by Segeberger Kliniken GmbH. The principal investigator is Gert Richardt, MD at Heart Center, Segeberger Kliniken. The trial plans to enroll 2,000 participants.